The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Cardiotoxicity associated with MCL-1 inhibition for R/R hematologic malignancies
Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, discusses the use of the MCL-1 inhibitor AZD5991 for relapsed or refractory (R/R) hematologic malignancies. Despite AZD5991 being discontinued due to cardiotoxicity, Dr Desai explains how it should encourage future studies to incorporate cardiotoxicity measures for more optimal development. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
